These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 1353449)

  • 21. Multiple fluorescent ligands for dopamine receptors. I. Pharmacological characterization and receptor selectivity.
    Barton AC; Kang HC; Rinaudo MS; Monsma FJ; Stewart-Fram RM; Macinko JA; Haugland RP; Ariano MA; Sibley DR
    Brain Res; 1991 May; 547(2):199-207. PubMed ID: 1679366
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis and biological evaluation of p-bromospiperone as potential neuroleptic drug.
    Huang CC; Friedman AM; So R; Simonovic M; Meltzer HY
    J Pharm Sci; 1980 Aug; 69(8):984-6. PubMed ID: 6105200
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Affinity probes for the GABA-gated chloride channel: 5e-tert-butyl-2e-[4-(substituted-ethynyl)phenyl]-1,3-dithianes with photoactivatable, fluorescent, biotin, agarose and protein substituents.
    Li QX; Casida JE
    Bioorg Med Chem; 1995 Dec; 3(12):1675-84. PubMed ID: 8770392
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immuno-photoaffinity labeling of the D2-dopamine receptor.
    Kanety H; Fuchs S
    Biochem Biophys Res Commun; 1988 Sep; 155(2):930-6. PubMed ID: 2458727
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structure-affinity relationship studies on D-2/5-HT1A receptor ligands. 4-(2-Heteroarylethyl)-1-arylpiperazines.
    Dukić S; Vujović M; Soskić V; Joksimović J
    Arzneimittelforschung; 1997 Mar; 47(3):239-43. PubMed ID: 9105540
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A partially rigid butyrophenone analog with extended conformation.
    Chan CC; Farmer PS
    Pharmazie; 1986 Dec; 41(12):835-6. PubMed ID: 2883672
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Photoaffinity labelling of dopamine D2 receptors by [3H]azidomethylspiperone.
    Niznik HB; Grigoriadis DE; Seeman P
    FEBS Lett; 1986 Dec; 209(1):71-6. PubMed ID: 2948835
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [3H]Pramipexole: a selective radioligand for the high affinity dopamine D2 receptor in bovine striatal membranes.
    Ohnmacht U; Tränkle C; Mohr K; Gmeiner P
    Pharmazie; 1999 Apr; 54(4):294-7. PubMed ID: 10234741
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differential localization of dopamine D1 and D2 receptors in rat retina.
    Tran VT; Dickman M
    Invest Ophthalmol Vis Sci; 1992 Apr; 33(5):1620-6. PubMed ID: 1532792
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular characterization of dopamine receptors.
    Bates MD; Gingrich JA; Bunzow JR; Falardeau P; Dearry A; Senogles SE; Civelli O; Caron MG
    Am J Hypertens; 1990 Jun; 3(6 Pt 2):29S-33S. PubMed ID: 2143386
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The affinity of aromatic fluoride derivatives of phenothiazine neuroleptics to spiroperidol binding sites of dopamine receptors by the radioligand technic in vitro].
    Oelssner W; Peinhardt G; Büge A
    Pharmazie; 1985 May; 40(5):341-2. PubMed ID: 2863832
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of the binding subunit of the D1-dopamine receptor by photoaffinity crosslinking.
    Amlaiky N; Berger JG; Chang W; McQuade RJ; Caron MG
    Mol Pharmacol; 1987 Feb; 31(2):129-34. PubMed ID: 3807891
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dihydrexidine, a novel full efficacy D1 dopamine receptor agonist.
    Mottola DM; Brewster WK; Cook LL; Nichols DE; Mailman RB
    J Pharmacol Exp Ther; 1992 Jul; 262(1):383-93. PubMed ID: 1352553
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel radioiodinated high affinity ligand for the D2-dopamine receptor. Characterization of its binding in bovine anterior pituitary membranes.
    Amlaiky N; Kilpatrick BF; Caron MG
    FEBS Lett; 1984 Oct; 176(2):436-40. PubMed ID: 6548453
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dopamine D1 and D2 receptor selectivities of agonists and antagonists.
    Seeman P; Ulpian C
    Adv Exp Med Biol; 1988; 235():55-63. PubMed ID: 2976254
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activity of N-(2-phenylethyl)-N-n-propyl-2-(3-hydroxyphenyl) ethylamine derivatives as dopamine receptor ligands.
    Claudi F; Cardellini M; Di Stefano A; Giorgioni G; Cantalamessa F; Renò F; Balduini W
    Drug Des Discov; 1994 Feb; 11(2):115-25. PubMed ID: 7915549
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chemical modification reveals involvement of tyrosine in ligand binding to dopamine D1 and D2 receptors.
    Srivastava LK; Mishra RK
    Biochem Int; 1990; 21(4):705-14. PubMed ID: 2241996
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Distinctions between ligand-binding sites for [3H]dopamine and D2 dopaminergic receptors characterized with [3H]spiroperidol.
    Hancock AA; Marsh CL
    Mol Pharmacol; 1984 Nov; 26(3):439-51. PubMed ID: 6238230
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthesis and binding properties of several new dopaminergic ligands.
    Tuce Z; Soskić V; Joksimović J
    Drug Des Discov; 1994 Jun; 11(4):251-8. PubMed ID: 7727678
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Guanine nucleotides reveal differential actions of ergot derivatives at D-2 receptors labelled by [3H]spiperone in striatal homogenates.
    Gundlach AL; Krstich M; Beart PM
    Brain Res; 1983 Nov; 278(1-2):155-63. PubMed ID: 6227373
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.